Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.

BMJ case reports - 23 Dec 2023

Lee Jimmy, Turetsky Jordan, Nasri Elham, Rogers Sherise C

Abstract excerpt

Malignant peritoneal mesothelioma (MPeM) is a rare malignancy with historically poor prognosis. Recent research has started to reveal increasingly prevalent genetic mutations seen in this malignancy. Here, we report a case of complete clinical remission of unresectable, metastatic MPeM with systemic chemotherapy. Immunohistochemistry of our patient's malignant cytology sample showed loss of Breast Cancer Gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab
Share to Lung Neoplasms
Share to Mesothelioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mesothelioma, Malignant

Share to Pemetrexed

Share to Peritoneal Neoplasms

Share to Tumor Suppressor Proteins

Share to Ubiquitin Thiolesterase

Source

Identifiers

PMID: 38142057
DOI: 10.1136/bcr-2023-255916

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.PMID 38142057Read ↗

Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.Semantic proximity Read ↗

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesotheliomaSemantic proximity Read ↗

Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.Semantic proximity Read ↗

Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.Semantic proximity Read ↗

Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.Semantic proximity Read ↗

BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal MesotheliomaSemantic proximity Read ↗

Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.Semantic proximity Read ↗

Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaSemantic proximity Read ↗

Genomic Landscape of Malignant Mesotheliomas.Semantic proximity Read ↗

Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural MesotheliomaSemantic proximity Read ↗

Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.Semantic proximity Read ↗

BAP1: Not just a BRCA1-associated proteinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.